NovaBay Pharmaceuticals, Inc. has regained compliance with NYSE American continued listing standards. This is a positive development for the company, indicating improved financial health or operational performance, which could boost investor confidence. Regaining compliance reduces the risk of delisting and may support stock stability. Investors should monitor NovaBay’s business strategy and market performance following this news.